Company Profile
DexCom, Inc. Stock Price, News & Analysis
- Ticker:
- DXCM
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
83.02 USD (+0.44%)
Close
Last updated: August 6, 2026
28.3B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, DXCM closed up 0.44% at $83.02. No new same-company headline was identified in the current news window.
Company overview
Business overview
DexCom is a leading medical technology company focused on continuous glucose monitoring for diabetes care. The company’s platform is built around connected sensors, recurring usage, and the expansion of CGM across broader patient populations.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, DexCom is a healthcare technology company with strong exposure to diabetes monitoring. It sits in device-driven chronic care rather than drug development.
Business Model Characteristics
DexCom generates revenue through sensor sales, platform adoption, and recurring glucose-monitoring usage. Investors track user growth, reimbursement, product launches, and whether the company can keep extending CGM beyond its core base.
Position Within the Biotechnology Landscape
DexCom is not biotech proper, but it is one of the most important diabetes technology names in healthcare. It is more about device adoption and recurring use than binary clinical or FDA-drug events.
Future catalysts
Dexcom’s watchlist is G7 adoption, international expansion, and sensor-cycle execution that supports recurring revenue. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of DexCom, Inc. (DXCM)?
DexCom, Inc. (DXCM) most recently closed at 83.02 USD, a +0.44% move versus the previous session.
What is the market cap of DexCom, Inc. (DXCM)?
DexCom, Inc. currently has a market capitalization of 28.3B USD on BioPharmSignal.
What does DexCom, Inc. do?
DexCom is a leading medical technology company focused on continuous glucose monitoring for diabetes care. The company’s platform is built around connected sensors, recurring usage, and the expansion of CGM across broader patient populations.
On which exchange is DXCM stock listed?
DexCom, Inc. (DXCM) is associated with NASDAQ, United States, Biopharma.
What is DexCom?
Dexcom’s watchlist is G7 adoption, international expansion, and sensor-cycle execution that supports recurring revenue.
Which conditions is DexCom, Inc. targeting with DexCom?
DexCom, Inc. is associated with diabetes based on its company overview and current catalyst commentary.
How does DexCom, Inc. describe recent progress with DexCom?
Dexcom’s watchlist is G7 adoption, international expansion, and sensor-cycle execution that supports recurring revenue.